Financial Data and Key Metrics Changes - Total members increased by 53% year over year to 831,000, with revenue growing by 49% year over year to $68 million [4][22] - GAAP gross margin reached 66%, while non-GAAP gross margin was at 68%, both showing significant improvement from the previous year [4][23] - The net loss was reduced to $3 million compared to $9 million in Q3 2024, marking a notable improvement in financial performance [4][24] - For the first time, the company achieved a positive adjusted EBITDA of $2 million, compared to a loss of $5 million in Q3 2024 [4][24] Business Line Data and Key Metrics Changes - The GLP-1 CareTrack program has been a significant driver of growth, reflecting strong demand and multi-condition adoption [11][22] - The company reported that 75% of new customers opted for multiple Omada programs, indicating the appeal of its integrated multi-condition platform [12] Market Data and Key Metrics Changes - The company has seen healthy activity in the current selling season, with early sales traction through a large new channel partner, representing an estimated 180,000 individuals [11] - The demand for GLP-1 offerings has been a key factor in the company's growth, with significant interest from employers and health plans [6][22] Company Strategy and Development Direction - The company plans to invest in GLP-1 offerings and AI technologies, aiming to enhance its solutions and widen its competitive moat [9][25] - The strategic focus is on delivering integrated care that combines clinical services with behavioral support, addressing the complexities of medication management [6][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for growth in 2026 and beyond, driven by innovations in GLP-1 therapies and AI integration [9][10] - The company aims to achieve sustained profitability while continuing to invest in key areas that can enhance its service offerings [25] Other Important Information - The company published its 30th peer-reviewed manuscript, demonstrating the effectiveness of its programs in reducing medical costs and improving health outcomes [18][19] - The company ended Q3 with cash and cash equivalents of $199 million, down from $223 million in Q2 2025, primarily due to debt repayment [25] Q&A Session Summary Question: Can you discuss the new GLP-1 prescribing initiative? - Management highlighted that the new prescribing capability will be integrated within the Omada Care program, allowing members to fulfill prescriptions at their chosen pharmacy [30][31] Question: What investments are needed to launch this new offering? - Management indicated that investments will be required across engineering, product, sales, and marketing to support the new prescribing functionality [39] Question: How is the selling season progressing? - Management noted that they are seeing strong multi-product penetration and healthy activity in the selling season, with double-digit volume deal growth year over year [40] Question: How does GLP-1 drive growth in the overall portfolio? - Management stated that while GLP-1 CareTrack contributes to growth, the majority of new members still come from non-GLP-1 offerings, reflecting a successful multi-product sales strategy [76]

Financial Performance & Growth - Total member growth reached 53%, increasing from 543,000 in Q3 2024 to 831,000 in Q3 2025[14] - Revenue grew by 49%, from $455 million in Q3 2024 to $680 million in Q3 2025[14] - Non-GAAP Gross Profit increased by 56%, from $297 million in Q3 2024 to $464 million in Q3 2025, with Gross Margins at 652% and 682% respectively[14] - Net loss improved by $6 million, decreasing from $(92) million in Q3 2024 to $(32) million in Q3 2025[14] - Adjusted EBITDA grew by $75 million, increasing from $(51) million in Q3 2024 to $24 million in Q3 2025[14] Business Model & Customer Base - The company has over 2,000 customers[16, 134] and a customer retention rate of over 90%[16, 134] - Over 20 million individuals have benefits coverage for one or more programs[16, 80] - The company's revenue model is recurring, tied to member success, and billable through payer claims for certain customers[16, 18] Market Opportunity & GLP-1 Strategy - The total current addressable market is estimated at $414 billion for prediabetes, $173 billion for diabetes, $316 billion for hypertension, and $448 billion for musculoskeletal conditions[24] - Enhanced GLP-1 Care Track members experienced 28% greater weight loss compared to members not enrolled in the track over the first 16 weeks[101] - Enhanced GLP-1 Care Track members maintained weight loss at 16 weeks post-discontinuation, with an average weight change of 08%[100, 101]

Core Insights - Omada Health is launching a new prescribing capability for anti-obesity medications (AOM), including GLP-1s, as part of its weight health program, following a 53% year-over-year member growth as of Q3 [1][2] Group 1: New Offerings and Capabilities - The new prescribing capability aims to provide tailored support throughout the member journey, from prescription to ongoing medication management [2][3] - Omada's approach combines behavioral intelligence with clinical eligibility and health metrics to enhance prescribing decisions and care plans [2][3] - The new capability will be available in all 50 states, allowing for a nationally scalable model to support employers in managing AOM spend and outcomes [3][4] Group 2: Clinical Effectiveness and Outcomes - Omada's Enhanced GLP-1 Care Track has shown a 28% greater weight loss on average at 4 months compared to standard care [5] - Members in Omada's GLP-1 Care Track maintained an average weight change of just 0.8% 12 months post-medication discontinuation, significantly better than the typical 11-12% weight gain seen in clinical trials [5] Group 3: Strategic Positioning and Market Context - The launch aligns with the broader access to GLP-1 medications and reflects a shift in focus from access to effective and safe usage for long-term outcomes [2] - Omada Health aims to address challenges faced by payers and employers in obesity management by combining prescription capabilities with lifestyle support [4]

Core Insights - Omada Health reported a revenue of $68 million for Q3 2025, representing a 49% increase year-over-year, with total members reaching 831,000, a 53% growth compared to Q3 2024 [1][7][8] - The company achieved a significant reduction in net loss, reporting a net loss of $3 million compared to $9 million in Q3 2024, and recorded its first quarter of positive adjusted EBITDA at $2 million [1][8] - Omada announced a new GLP-1 prescribing offering aimed at enhancing member health outcomes and providing cost savings for customers [1][7][8] Financial Performance - Revenue for Q3 2025 was $68 million, up 49% from $45.5 million in Q3 2024 [7][8] - Gross margin improved to 66%, up from 63% in the same quarter last year, with a non-GAAP gross margin of 68% [8] - Adjusted EBITDA was reported at $2 million, a significant improvement from an adjusted EBITDA loss of $5 million in Q3 2024 [8] Member Growth and Offerings - Total members increased to 831,000, marking a 53% growth compared to the previous year [7] - The new GLP-1 prescribing offering will integrate Omada's behavior change program with medication management for anti-obesity medications [7] - The company published its 30th peer-reviewed manuscript, demonstrating cost savings from its Joint & Muscle Health program and showing that members largely maintained their weight one year after discontinuing GLP-1 therapy [7] Cash Position and Financial Outlook - Cash and cash equivalents stood at $199 million as of September 30, 2025 [8] - For the full year 2025, Omada expects revenue in the range of $251.5 million to $254.5 million, an increase from the previous range of $235 million to $241 million [8]

Omada Health Reports Third Quarter 2025 Results Revenue of $68 million, up 49%; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO - November 6, 2025 - Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarter Highlights "Our third quarter results demonstrate the strength of Omada's mu ...

Core Insights - Omada Health will begin prescribing GLP-1s and other obesity medications, expanding its weight management program as membership surpasses 100,000 [1][6] Industry Overview - The digital health sector is increasingly entering the GLP-1 market, which could reach approximately $100 billion by the end of the decade [2] - Major manufacturers like Eli Lilly and Novo Nordisk are working to enhance accessibility and develop new treatments for obesity and chronic conditions [2] Company Strategy - Omada's CEO, Sean Duffy, believes that access to GLP-1s will significantly increase over time, with a market expansion expected to include pills and next-generation treatments [3] - The company aims to support lifestyle and behavioral changes for patients on GLP-1s, providing resources such as nutrition guidance and health coaching [4] Patient Support - The new offering will assist patients from the prescription stage through their treatment, addressing complexities and side effects associated with GLP-1 injections [5] - Omada collaborates with licensed providers trained in obesity care to enhance medication management for patients [4][5] Financial and Operational Context - Omada partners with health plans and employers to better support employee health needs while managing costs related to obesity treatments [6] - The company reported its quarterly earnings for the second time since its IPO in June [6][7]

Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistenceSAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada’s behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance resu ...

Core Insights - Omada Health has appointed Dr. Thomas Tsang as Chief Medical Officer to lead its clinical organization and enhance clinical quality and innovation [1][2][4] Company Overview - Omada Health is a virtual-first healthcare provider focused on chronic conditions such as diabetes, hypertension, and musculoskeletal issues, serving over 2,000 customers including health plans and Fortune 500 companies [5][6] - The company has implemented clinically-validated behavior change protocols and has over a decade of experience with 30 peer-reviewed publications demonstrating its clinical and economic results [5] Leadership and Experience - Dr. Tsang has a strong background in virtual care delivery, having previously served as founding CEO of Valera Health, where he raised over $75 million and scaled the company to over 500 employees [2][3] - His experience includes roles as Chief Medical Officer at Merck Healthcare Services and as a Medical Director under the Obama Administration, contributing to national health policy and electronic health records [3] Strategic Initiatives - Omada is expanding its GLP-1 Care Track, which has served over 100,000 members since its launch, and enhancing its AI capabilities with tools like OmadaSpark and Meal Map for personalized nutrition [4] - The company aims to combine innovative technology with human-led care to improve member engagement and health outcomes [4]

Core Insights - Omada Health will release its third quarter 2025 results on November 6, 2025, after market close, followed by a conference call at 4:30 pm ET [1] Company Overview - Omada Health is a virtual-first healthcare provider focused on lifelong health, utilizing clinically-validated behavior change protocols for conditions such as diabetes, hypertension, prediabetes, and musculoskeletal issues [3] - The company has over a decade of experience, supported by 30 peer-reviewed publications demonstrating its clinical and economic outcomes [3] - Omada serves more than 2,000 customers, including health plans, health systems, and employers from small businesses to Fortune 500 companies [3] Company Culture and Recognition - Omada Health has established a strong work culture, earning the certification as a Great Place to Work [4] - The company was the first virtual provider to join the Institute for Healthcare Improvement's Leadership Alliance, emphasizing its commitment to complementing primary care providers [4]

Group 1 - Evercore ISI analyst Elizabeth Anderson has added Omada Health (OMDA) to the firm's "Tactical Outperform" list as part of an update on estimates and tactical calls in the Healthcare Technology & Distribution group ahead of Q3 earnings season [1] - The firm maintains an Outperform rating on Omada shares with a price target set at $27 [1]